ZNTL
Zentalis Pharmaceuticals, Inc. · Healthcare · Market cap $217.2M
Insiders bought $15.2M net in the last 90 days ·0 sellers, 1 buyer· latest Form 4 filed Aug 19, 2026
Insider Buying
$22.9M
reported purchases (SEC code P)
Insider Selling
$10.1M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Aug 19, 2026
WALTERS GROUP
Zentalis Pharmaceuticals, Inc. (ZNTL) has 13 SEC Form 4 filings (18 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Aug 19, 2026.
Inside the rolling window, 5 insiders at Zentalis Pharmaceuticals, Inc. reported 2 open-market purchases totaling $22.9M and 10 open-market sales totaling $10.1M. The most active filer is PAO and PFO Vultaggio Vincent with 5 filings. Insiders have net bought $15.2M over the trailing 6 months. The largest single insider purchase in this window was $15.2M by 10% Owner WALTERS GROUP on Aug 14, 2026.
- Industry:Biotechnology
- CEO:Julia Marie Eastland
- Employees:106
- HQ:San Diego, CA, US
- IPO:2020-04-03
| Source | |||||||
|---|---|---|---|---|---|---|---|
WALTERS GROUPFirst in 7 months | 10% Owner | Purchase | 4,335,000 | $15.2M | Aug 19 | -20.7% | SEC ↗ |
| PAO and PFO | Sale | 29,951 | $73K | Feb 10 | +26.2% | SEC ↗ | |
| PAO and PFO | Sale | 3,379 | $8K | Feb 10 | +26.2% | SEC ↗ | |
| PAO and PFO | Sale | 6,894 | $17K | Feb 10 | +26.2% | SEC ↗ | |
EASTLAND JULIA MARIEFirst filing | CEO & President | Sale | 7,866 | $19K | Feb 10 | +26.2% | SEC ↗ |
EASTLAND JULIA MARIEFirst filing | CEO & President | Sale | 889 | $2K | Feb 10 | +26.2% | SEC ↗ |
Bruns IngmarFirst filing | Chief Medical Officer | Sale | 2,962 | $7K | Feb 10 | +26.2% | SEC ↗ |
Bruns IngmarFirst filing | Chief Medical Officer | Sale | 335 | $802 | Feb 10 | +26.2% | SEC ↗ |
Vultaggio VincentFirst filing | PAO and PFO | Sale | 2,540 | $6K | Feb 4 | +18.8% | SEC ↗ |
Vultaggio VincentFirst filing | PAO and PFO | Sale | 556 | $1K | Feb 4 | +18.8% | SEC ↗ |
WALTERS GROUPFirst filing | 10% Owner | Purchase | 6,459,973 | $7.8M | Jan 8 | — | SEC ↗ |
Matrix Capital Management Company, LPFirst filing | 10% Owner | Sale | 7,500,000 | $10.0M | Dec 15 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does ZNTL have?
Zentalis Pharmaceuticals, Inc. (ZNTL) has 13 SEC Form 4 filings (18 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Aug 19, 2026.
When was the most recent SEC Form 4 filing for ZNTL?
The most recent Form 4 filing for ZNTL on Tracefour is dated Aug 19, 2026.
Who is the most active insider at ZNTL?
The most active SEC Form 4 filer at ZNTL in the rolling window is PAO and PFO Vultaggio Vincent, with 5 filings.
What is the net insider flow at ZNTL over the last 6 months?
Over the trailing 180 days, insiders at ZNTL have net bought $15.2M based on SEC Form 4 disclosures.
What was the largest insider purchase at ZNTL?
The largest single insider open-market purchase at ZNTL in the rolling window was $15.2M by 10% Owner WALTERS GROUP on 2026-08-14.
What is the total insider buy and sell value at ZNTL in the current window?
Inside the rolling window, insiders at ZNTL bought $22.9M and sold $10.1M based on SEC Form 4 filings.
Can I get alerts for ZNTL insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Zentalis Pharmaceuticals, Inc. (ZNTL). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Zentalis Pharmaceuticals, Inc. is in the Healthcare sector.